Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nafamostat mesylate in aspect of treating colorectal cancer

A technology for nafamostat mesylate and colorectal cancer, which is applied in the field of medicine and can solve problems such as no application report of nafamostat mesylate.

Inactive Publication Date: 2016-04-06
SUN YAT SEN UNIV CANCER CENT
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there are no reports on the application of nafalimus mesylate in other diseases such as other cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nafamostat mesylate in aspect of treating colorectal cancer
  • Application of nafamostat mesylate in aspect of treating colorectal cancer
  • Application of nafamostat mesylate in aspect of treating colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] The influence of embodiment 1 nafamostat mesylate on colon cancer cells and tumor formation

[0039] 1. Experimental materials

[0040] (1) Drug: nafamostat mesylate.

[0041] (2) Colorectal cancer cells: human colon cancer cells HCT116 and human colon adenocarcinoma cells SW1116.

[0042] (3) Apoptosis kit.

[0043] (4) Female nude mice, 4-5 weeks old.

[0044] 2. Experimental grouping

[0045] (1) Control group: blank control, that is, colorectal cancer cells were not treated with any drugs.

[0046] (2) Experimental group: colorectal cancer cells were treated with nafamostat mesylate.

[0047] 3. The effect of nafamostat mesylate on the apoptosis of colorectal cancer cells detected by flow cytometry

[0048] (1) We paved colorectal cancer cells in six-well plates, and after they adhered to the wall, added 200 μM nafamostat mesylate to treat the cells for 48 hours, and then detected cell apoptosis by flow cytometry.

[0049] The specific method is as follows:...

Embodiment 2

[0064] Example 2 Effect of nafamostat mesylate on expression of colorectal cancer cell signaling pathway proteins

[0065] 1. Experimental materials

[0066] (1) Drug: nafamostat mesylate.

[0067] (2) Colorectal cancer cells: human colon cancer cells HCT116, SW620 and human colon adenocarcinoma cells SW1116.

[0068] (3) IκBα, p-IκBα, Erk, p-Erk and GAPDH antibodies.

[0069] 2. Western blotting method to detect the effect of nafamostat mesylate on the expression of signaling pathway proteins in colorectal cancer cells

[0070] (1) We paved the colorectal cancer cells in a six-well plate, and after they adhered to the wall, we added 50 μM and 100 μM nafamostat mesylate to treat the cells for 24 hours, and then detected nafamostat mesylate by immunoblotting His expression of signaling pathway proteins in colorectal cancer cells.

[0071] The specific method is as follows:

[0072] 1) HCT116, SW1116 and SW620 cells in the logarithmic growth phase were digested with trypsin...

Embodiment 3

[0078] Example 3 Effect of nafamostat mesylate on the proliferation of colorectal cancer cells

[0079] 1. Experimental materials

[0080] (1) Drug: nafamostat mesylate.

[0081] (2) Colorectal cancer cells: human colon cancer cells HCT116 and human colon adenocarcinoma cells SW1116.

[0082] (3) CCK-8 kit.

[0083] 2. Detect the viability of HCT116 and SW1116 cells after nafamostat mesylate treatment by CCK-8 method

[0084] (1) We spread colorectal cancer cells in a 96-well plate, and after they adhered to the wall, we added 0 μM, 200 μM, and 300 μM nafamostat mesylate to treat the cells, and then treated the cells at 6h, 12h, 24h, 36h, and 48h. The cell viability of HCT116 and SW1116 was detected by CCK-8 method.

[0085] The specific method is as follows:

[0086] 1) HCT116, SW1116 and SW620 cells in the logarithmic growth phase were digested with trypsin, and 4×10 3 Cells were spread evenly into 96-well plates.

[0087] 2) After 12 hours, the cells adhered to the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of nafamostat mesylate in aspect of preparing a medicine for treating colorectal cancer, and application of the combination of nafamostat mesylate and oxaliplatin in preparing a medicine for treating the colorectal cancer. Researches show that the nafamostat mesylate can be used for significantly inhibiting the growth and the proliferation of colorectal cancer cells, obviously inhibiting the growth and volume increase of the colorectal cancer, inducing apoptosis of the colorectal cancer cells and inhibiting transfer of the colorectal cancer cells, and the nafamostat mesylate, which has a significant curative effect on the colorectal cancer, can be applied to the aspect of preventing and treating the colorectal cancer. The invention not only provides novel application of the nafamostat mesylate and offers a new field for the application of the nafamostat mesylate, but also provides a novel therapeutic drug and therapeutic approach for the treatment of the colorectal cancer. Moreover, the invention also offers a novel scheme for the treatment of the colorectal cancer with the combination of the nafamostat mesylate and the oxaliplatin, and the scheme has a more obvious therapeutic effect on the colorectal cancer.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of nafamostat mesylate in the treatment of colorectal cancer. Background technique [0002] Nafamostat mesilate is a protease inhibitor that mainly exerts anti-inflammatory effects by inhibiting tryptase in mast cells. It has been approved by the FDA for the treatment of pancreatitis and disseminated intravascular coagulation. Can be used as an anticoagulant during hemodialysis. [0003] Recent studies have shown that nafamostat mesylate can kill pancreatic cancer cells to a certain extent, and has a certain anti-pancreatic cancer effect in nude mouse animal models. [0004] At present, there are no reports on the application of nafalimus mesylate in other diseases such as other cancers. Contents of the invention [0005] The technical problem to be solved by the present invention is to overcome the application limitations and shortcomings of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/245A61P35/00A61P35/04A61K31/282
CPCA61K31/245A61K31/555A61K2300/00
Inventor 徐瑞华鲁运新鞠怀强王峰
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com